KOL And Patient Interviews
1 February, 2024
FULL VIDEO INTERVIEW: Prof. Harrison discusses the clinical relevance of HaemaLogiX's targets, KMA & LMA
8 February, 2024
INTERVIEW SNIPPET: Prof. Harrison explains his motivation to join the HaemaLogiX Scientific Advisory Board
8 February, 2024
INTERVIEW SNIPPET: Prof. Harrison explains why the science behind HaemaLogiX's technology makes sense
8 February, 2024
INTERVIEW SNIPPET: Prof. Harrison discusses the clinical relevance of HaemaLogiX's targets, KMA & LMA
1 February, 2024
FULL VIDEO INTERVIEW: Professor Andrew Spencer discusses the clinical relevance of HaemaLogiX’s targets KMA and LMA, and the clinical opportunity for our multi-platform portfolio of immunotherapy assets
8 February, 2024
INTERVIEW SNIPPET: Prof. Spencer explain the importance of HaemaLogiX's upcoming POM/DEX/KAPPA Trial
8 February, 2024
INTERVIEW SNIPPET: Prof. Spencer discuss the outcomes of HaemaLogiX's KappaMab Phase 2 Trial
8 February, 2024
INTERVIEW SNIPPET: Prof. Spencer discusses the clinical relevance of HaemaLogiX’s targets, KMA & LMA
19 June 2024
HaemaLogiX CSO Dr Rosanne Dunn explains the key highlights of the abstract that was recently published on the European Hematology Association (EHA)
26 May 2023
Karen Wilde, myeloma patient story - Short Video
26 May 2023
Karen Wilde, myeloma patient story - Long Video